先进的人类乳头瘤病毒阴性头状细胞癌:未满足的需求和新兴疗法
Robin Park1, Christine H Chung1
1Department of Head and Neck-Endocrine Oncology, Moffitt Cancer Center, Tampa, Florida.
Molecular cancer therapeutics
|September 20, 2024
概括
对于复发性,转移性HPV阴性头支状细胞癌 (HNSCC),EGFR和c-MET通路的双重向显示出有希望. 将这些抑制剂结合起来,可以克服对 cetuximab 的耐药性,改善这种具有挑战性的癌症的治疗结果.
科学领域:
- 在瘤学瘤学.
- 癌症研究 癌症研究
- 头部和部癌症 头部和部癌症
背景情况:
- 尽管治疗进展,但高级头部和部状细胞癌 (HNSCC),特别是HPV阴性病例的存活率很低.
- 阴性HPVHNSCC与细胞循环调节器损失,瘤抑制剂缺陷以及抗性,缺氧瘤微环境有关.
- 目前的标准治疗,即抗编程细胞死亡蛋白1 (PD-1) 疗法,仅在一小部分患者中提供持久反应.
研究的目的:
- 审查治疗复发性和/或转移性 (R/M) 阴性HPVHNSCC的临床数据.
- 探索双重EGFR和c-MET通路抑制的潜力,以克服 cetuximab 的耐药性.
- 确定改善R/MHPV阴性HNSCC治疗结果的策略.
主要方法:
- 对R/M HNSCC治疗的临床试验数据的审查.
- 对 cetuximab 的耐药性机制的分析,包括 EGFR 和 c-MET 途径交叉.
- 针对EGFR和c-MET的组合疗法的评估.
主要成果:
- 塞图西马布表现出抗瘤活性,但受到获得的耐药性限制.
- EGFR和c-MET通路之间的交叉是 cetuximab 耐药性的关键机制.
- 为了克服这种抗性,正在研究双抑制策略.
结论:
- 对EGFR和c-MET途径的双重向为R/MHPV阴性HNSCC提供了一个有希望的策略.
- 组合疗法可以克服 cetuximab 的耐药性,并改善患者的生存率.
- 需要对结合EGFR和c-MET抑制剂进行进一步的临床评估.
更多相关视频
07:29Intramucosal Inoculation of Squamous Cell Carcinoma Cells in Mice for Tumor Immune Profiling and Treatment Response Assessment
Published on: April 22, 2019
11.5K
10:26RNAscope for In situ Detection of Transcriptionally Active Human Papillomavirus in Head and Neck Squamous Cell Carcinoma
Published on: March 11, 2014
27.3K
相关概念视频
01:30Cancer Vaccines
345
Cancer treatment vaccines are a rapidly evolving field that offers a promising approach to immunotherapy. Unlike traditional vaccines that prevent diseases, cancer treatment vaccines are designed to treat existing cancers by stimulating the immune system to recognize and attack cancer cells.
Cancer vaccines come in two categories: preventive (prophylactic) and treatment (active). Preventive vaccines, such as the Human Papillomavirus (HPV) vaccine, protect against viruses that cause certain...
Cancer vaccines come in two categories: preventive (prophylactic) and treatment (active). Preventive vaccines, such as the Human Papillomavirus (HPV) vaccine, protect against viruses that cause certain...
345
02:57Targeted Cancer Therapies
7.5K
The targeted cancer therapies, also known as “molecular targeted therapies,” take advantage of the molecular and genetic differences between the cancer cells and the normal cells. It needs a thorough understanding of the cancer cells to develop drugs that can target specific molecular aspects that drive the growth, progression, and spread of cancer cells without affecting the growth and survival of other normal cells in the body.
There are several types of targeted therapies against...
There are several types of targeted therapies against...
7.5K
02:49Cancer Therapies
7.6K
Cancer therapies are various modes of treatment, such as surgery, radiation therapy, and chemotherapy that are administered to cancer patients.
However, cancer treatments can pose several challenges, as therapies used to kill cancer cells are generally also toxic to normal cells. Moreover, cancer cells mutate rapidly and can develop resistance to chemical agents or radiation therapy. Besides, all types of cancer cells may not respond to the same therapy. Some cancer cells respond to one...
However, cancer treatments can pose several challenges, as therapies used to kill cancer cells are generally also toxic to normal cells. Moreover, cancer cells mutate rapidly and can develop resistance to chemical agents or radiation therapy. Besides, all types of cancer cells may not respond to the same therapy. Some cancer cells respond to one...
7.6K
01:27Tumor Immunotherapy
491
Immunotherapy is a treatment that boosts or manipulates the immune system to fight diseases, including cancer. For instance, by stimulating an immune response through vaccinations against viruses that cause cancers, like hepatitis B virus and human papillomavirus, these diseases can be prevented. Nonetheless, some cancer cells can avoid the immune system due to their rapid mutation and division. The immune response to many cancers involves three phases: elimination, equilibrium, and escape.
491